Metabolism of designer drugs of abuse: An updated review

Current Drug Metabolism

Volumn 11, Issue 5, 2010, Pages 468-482

  Meyer, Markus R ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Beta keto amphetamines; Cytochrome P450; Designer drugs; Fentanyls; Monoamineoxidase; Phencyclidines; Phenethylamines; Pyrrolidinophenones; Tryptamines

Indexed keywords

2 ETHYLAMINO 1 (3,4 METHYLENEDIOXYPHENYL)PROPAN 1 ONE; 2 METHYLAMINO 1 (3,4 METHYLENEDIOXYPHENYL)BUTAN 1 ONE; 2 METHYLAMINO 1 (3,4 METHYLENEDIOXYPHENYL)PROPAN 1 ONE; 2 METHYLAMINO 1 4 TOLYLPROPANE 1 ONE; 2,5 DIMETHOXY 4 METHYL BETA PHENETHYLAMINE; 2,5 DIMETHOXY 4 PROPYLTHIO BETA PHENETHYLAMINE; 4 BROMO 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 ETHYL 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 ETHYLTHIO 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 IODO 2,5 DIMETHOXY BETA PHENETHYLAMINE; 4 METHYL PYRROLIDINOBUTYROPHENONE; ALPHA METHYLFENTANYL; ALPHA PYRROLIDINOVALEROPHENONE; BETA HYDROXYMEFENTANYL; FENTANYL DERIVATIVE; KETONE DERIVATIVE; N (1 PHENYL CYCLOHEXYL) 2 ETHOXYETHANAMINE; N (1 PHENYLCYCLOHEXYL) 3 METHOXYPROPANAMINE; N (1 PHENYLCYCLOHEXYL)PROPANAMINE; N (1 PHENYLCYPHENYLCYCLOHEXYL) 2 METHOXYETHANAMINE; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE; PHENCYCLIDINE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT; DESIGNER DRUG; PSYCHEDELIC AGENT;

DRUG ABUSE; DRUG CLEARANCE; DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; KINETICS; NONHUMAN; REVIEW; ANIMAL; BIOTRANSFORMATION; METABOLISM;

ANIMALS; BIOTRANSFORMATION; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; HALLUCINOGENS; HUMANS;

EID: 77953493759     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791526042     Document Type: Review

References (138)

1. Ewald, A.H.; Fritschi, G.; Bork, W.R.; Maurer, H.H. Designer drugs 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom., 2006, 41(4), 487-498. (Pubitemid 43668077)
2. Ewald, A.H.; Fritschi, G.; Maurer, H.H. Designer drug 2,4,5-trimethoxyamphetamine (TMA-2): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom., 2006, 41(9), 1140-1148. (Pubitemid 44454167)
3. Ewald, A.H.; Fritschi, G.; Maurer, H.H. Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxyamphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. J Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 857(1), 170-174. (Pubitemid 47362858)
4. Ewald, A.H.; Puetz, M.; Maurer, H.H. Designer drug 2,5-dimethoxy-4- methyl-amphetamine (DOM, STP): Involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 862(1-2), 252-256.
5. Ewald, A.H.; Ehlers, D.; Maurer, H.H. Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem., 2008, 390(7), 1837-1842.
6. Balikova, M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci. Int., 2005, 153(1), 85-91.
7. Theobald, D.S.; Staack, R.F.; Puetz, M.; Maurer, H.H. New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom., 2005, 40(9), 1157-1172. (Pubitemid 41337244)
8. Theobald, D.S.; Fehn, S.; Maurer, H.H. New designer drug 2,5-dimethoxy-4-propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom., 2005, 40(1), 105-116. (Pubitemid 40188987)
9. Theobald, D.S.; Maurer, H.H. Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxybeta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 842(2), 76-90. (Pubitemid 44416629)
10. Theobald, D.S.; Maurer, H.H. Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta-phenethylamine (2C-D) in rat urine using gas chromatographic-mass spectrometric techniques. J. Mass Spectrom., 2006, 41(11), 1509-1519. (Pubitemid 44875661)
11. Theobald, D.S.; Putz, M.; Schneider, E.; Maurer, H.H. New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J. Mass Spectrom., 2006, 41(7), 872-886. (Pubitemid 44106048)
12. Theobald, D.S.; Fritschi, G.; Maurer, H.H. Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatographymass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 846(1-2), 374-377. (Pubitemid 46149509)
13. Kamata, H.T.; Shima, N.; Zaitsu, K.; Kamata, T.; Miki, A.; Nishikawa, M.; Katagi, M.; Tsuchihashi, H. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica, 2006, 36(8), 709-723. (Pubitemid 44195985)
14. Zaitsu, K.; Katagi, M.; Kamata, H.T.; Kamata, T.; Shima, N.; Miki, A.; Tsuchihashi, H.; Mori, Y. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci. Int., 2009, 188(1-3), 131-139.
15. Sauer, C.; Peters, F.T.; Staack, R.F.; Fritschi, G.; Maurer, H.H. New designer drug (1-(1-phenylcyclohexyl)-3-ethoxypropylamine (PCEPA): Studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom., 2006, 41(8), 1014-1029. (Pubitemid 44338553)
16. Sauer, C.; Peters, F.T.; Staack, R.F.; Fritschi, G.; Maurer, H.H. New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom., 2008, 43(3), 305-316.
17. Sauer, C.; Peters, F.T.; Staack, R.F.; Fritschi, G.; Maurer, H.H. Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. A, 2008, 1186(1-2), 380-390.
18. Sauer, C.; Peters, F.T.; Staack, R.F.; Fritschi, G.; Maurer, H.H. Metabolism and toxicological detection of the designer drug N-(1- phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry. Forensic Sci. Int., 2008, 181(1-3), 47-51.
19. Maurer, H.H.; Kraemer, T.; Springer, D.; Staack, R.F. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types, a synopsis [review]. Ther. Drug Monit., 2004, 26(2), 127-131.
20. Staack, R.F.; Fritschi, G.; Maurer, H.H. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 773(1), 35-46. (Pubitemid 34518268)
21. Staack, R.F.; Maurer, H.H. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 798(2), 333-342. (Pubitemid 37487734)
22. Staack, R.F.; Maurer, H.H. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J. Anal. Toxicol., 2003, 27(8), 560-568.
23. Staack, R.F.; Fritschi, G.; Maurer, H.H. New designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom., 2003, 38(9), 971-981. (Pubitemid 37121814)
24. Staack, R.F.; Maurer, H.H. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom., 2004, 39(3), 255-261.
25. Tsutsumi, H.; Katagi, M.; Miki, A.; Shima, N.; Kamata, T.; Nakajima, K.; Inoue, H.; Kishi, T.; Tsuchihashi, H. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP) in rats. Xenobiotica, 2005, 35(1), 107-116.
26. Tsutsumi, H.; Katagi, M.; Miki, A.; Shima, N.; Kamata, T.; Nakajima, K.; Inoue, H.; Kishi, T.; Tsuchihashi, H. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-Benzylpiperazine (BZP) in the rat. J. Anal. Toxicol., 2006, 30(1), 38-43.
27. Tsutsumi, H.; Katagi, M.; Miki, A.; Shima, N.; Kamata, T.; Nishikawa, M.; Nakajima, K.; Tsuchihashi, H. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci, 2005, 819(2), 315-322. (Pubitemid 40521967)
28. Staack, R.F.; Maurer, H.H. Metabolism of designer drugs of abuse [review]. Curr. Drug Metab., 2005, 6(3), 259-274.
29. Peters, F.T.; Meyer, M.R.; Fritschi, G.; Maurer, H.H. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 824(1-2), 81-91. (Pubitemid 41215584)
30. Sauer, C.; Peters, F.T.; Haas, C.; Meyer, M.R.; Fritschi, G.; Maurer, H.H. New designer drug alpha-pyrrolidinovalerophenone (PVP): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom., 2009, 44(6), 952-964.
31. Springer, D.; Peters, F.T.; Fritschi, G.; Maurer, H.H. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 773(1), 25-33. (Pubitemid 34518267)
32. Springer, D.; Peters, F.T.; Fritschi, G.; Maurer, H.H. New designer drug 4′-methyl-alpha-pyrrolidinohexanophenone: Studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 789(1), 79-91. (Pubitemid 36513789)
33. Springer, D.; Fritschi, G.; Maurer, H.H. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 796(2), 253-266. (Pubitemid 37329670)
34. Springer, D.; Fritschi, G.; Maurer, H.H. Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxyalpha- pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 793(2), 377-388. (Pubitemid 37271978)
35. Springer, D.; Fritschi, G.; Maurer, H.H. Metabolism and toxicological detection of the new designer drug 4′-methoxy-α- pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 793(2), 331-342. (Pubitemid 37271973)
36. Meatherall, R.; Sharma, P. Foxy, a designer tryptamine hallucinogen. J. Anal. Toxicol., 2003, 27(5), 313-317.
37. Tanaka, E.; Kamata, T.; Katagi, M.; Tsuchihashi, H.; Honda, K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci. Int., 2006, 163(1-2), 152-154.
38. Wilson, J.M.; McGeorge, F.; Smolinske, S.; Meatherall, R. A foxy intoxication. Forensic Sci. Int., 2005, 148(1), 31-36.
39. Sanders, B.; Lankenau, S.E.; Bloom, J.J.; Hathazi, D. "Research chemicals": tryptamine and phenethylamine use among high-risk youth. Subst. Use Misuse, 2008, 43(3-4), 389-402. (Pubitemid 351448725)
40. Muller, A.A. New drugs of abuse update: Foxy Methoxy. J. Emerg. Nurs., 2004, 30(5), 507-508. (Pubitemid 39562226)
41. Shulgin, A.T.; Carter, M.F. N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol., 1980, 4(5), 363-369.
42. Ayres, W.A.; Starsiak, M.J.; Sokolay, P. The bogus drug: three methyl & alpha methyl fentanyl sold as "China White". J. Psychoactive Drugs, 1981, 13(1), 91-93.
43. Higashikawa, Y.; Suzuki, S. Studies on 1-(2-phenethyl)-4-(N- propionylanilino) piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methylsubstituted fentanyls and other analogues. Forens. Toxicol., 2008, 26(1), 1-5.
44. Higashikawa, Y.; Suzuki, S. Studies on 1-(2-phenethyl)-4- (Npropionylanilino) piperidine (fentanyl) and its related compounds: Novel metabolites in rat urine following injection of á-methylfentanyl, one of the most abused typical designer drugs. J. Health Sci, 2008, 54(6), 629-637. (Pubitemid 352791995)
45. Antia, U.; Tingle, M.D.; Russell, B.R. Metabolic interactions with piperazine-based 'party pill' drugs. J. Pharm. Pharmacol., 2009, 61(7), 877-882.
46. Nakagawa, Y.; Suzuki, T.; Tayama, S.; Ishii, H.; Ogata, A. Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch. Toxicol., 2009, 83(1), 69-80.
47. Austin, H.; Monasterio, E. Acute psychosis following ingestion of 'Rapture'. Australas. Psychiatry, 2004, 12(4), 406-408.
48. Kalant, H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs [review]. Can. Med. Assoc. J., 2001, 165(7), 917-928.
49. Mueller, M.; Yuan, J.; Felim, A.; Neudörffer, A.; Peters, F.T.; Maurer, H.H.; McCann, U.D.; Largeron, M.; Ricaurte, G.A. Further studies on the role of metabolites in MDMA-induced serotonergic neurotoxicity. Drug Metab. Dispos., 2009, 37(10), 2079-2086.
50. Wood, D.M.; Dargan, P.I.; Button, J.; Holt, D.W.; Ovaska, H.; Ramsey, J.; Jones, A.L. Collapse, reported seizure - and an unexpected pill. Lancet, 2007, 369(9571), 1490.
51. Maurer, H.H. Chemistry, pharmacology and metabolism of emerging drugs of abuse. Ther. Drug Monit., 2010, in press.
52. Hiramatsu, M.; Kumagai, Y.; Unger, S.E.; Cho, A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther., 1990, 254(2), 521-527.
53. Kraemer, T.; Maurer, H.H. Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives [review]. Ther. Drug Monit., 2002, 24(2), 277-289.
54. Meyer, M.R.; Maurer, H.H. Metabolism of amphetamine derivatives and their derived designer drugs: an updated review [review]. Drug Metab. Rev., 2010, in preparation.
55. Shulgin, A. Pihkal, A Chemical Love Story, 1st ed.; Transform Press: Berkley (CA), 1991.
56. de Boer, D.; Bosman, I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci., 2004, 26(2), 110-113. (Pubitemid 38418600)
57. Johnson, M.P.; Mathis, C.A.; Shulgin, A.T.; Hoffman, A.J.; Nichols, D.E. [125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav., 1990, 35(1), 211-217.
58. Glennon, R.A.; Raghupathi, R.; Bartyzel, P.; Teitler, M.; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1992, 35(4), 734-740.
59. Glennon, R.A.; Titeler, M.; Lyon, R.A. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol. Biochem. Behav., 1988, 30(3), 597-601.
60. Monte, A.P.; Marona-Lewicka, D.; Parker, M.A.; Wainscott, D.B.; Nelson, D.L.; Nichols, D.E. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl) alkylamine derivatives with rigidified methoxy groups. J. Med. Chem., 1996, 39(15), 2953-2961.
61. Acuna-Castillo, C.; Villalobos, C.; Moya, P.R.; Saez, P.; Cassels, B.K.; Huidobro-Toro, J.P. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br. J. Pharmacol., 2002, 136(4), 510-519.
62. Villalobos, C.A.; Bull, P.; Saez, P.; Cassels, B.K.; Huidobro-Toro, J.P. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol., 2004, 141(7), 1167-1174.
63. Fantegrossi, W.E.; Harrington, A.W.; Eckler, J.R.; Arshad, S.; Rabin, R.A.; Winter, J.C.; Coop, A.; Rice, K.C.; Woods, J.H. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl.), 2005, 181(3), 496-503.
64. Glennon, R.A.; Kier, L.B.; Shulgin, A.T. Molecular connectivity analysis of hallucinogenic mescaline analogs. J. Pharm. Sci., 1979, 68(7), 906-907.
65. Gupta, S.P.; Bindal, M.C.; Singh, P. Quantitative structure-activity studies on hallucinogenic mescaline analogs using modified first order valence connectivity. Arzneim. -Forsch., 1982, 32(10), 1223-1225. (Pubitemid 12034268)
66. Kier, L.B.; Glennon, R.A. Progress with several models for the study of the SAR of hallucinogenic agents. NIDA Res. Monogr., 1978, 22, 159-185.
67. Beuerle, G.; Kovar, K.A.; Schulze-Alexandru, M. Three-dimensional quantitative structure-activity relationships of hallucinogenic phenylalkanamine and tryptamine derivatives. Studies using comparative molecular field analysis (CoMFA). Quant. Struct. -Act. Relat., 1997, 16(6), 447-458. (Pubitemid 28055264)
68. Bienfait, B. Applications of high-resolution self-organizing maps to retrosynthetic and QSAR analysis. J. Chem. Inf. Comput. Sci., 1994, 34(4), 890-898.
69. Clare, B.W. The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. J. Med. Chem., 1998, 41(20), 3845-3856.
70. Klopman, G.; Macina, O.T. Use of the Computer Automated Structure Evaluation program in determining quantitative structure-activity relationships within hallucinogenic phenylalkylamines. J. Theor. Biol., 1985, 113(4), 637-648.
71. Mracec, M.; Mracec, M.; Kurunczi, L.; Nusser, T.; Simon, Z.; Naray-Szabo, G. QSAR study with steric (MTD), electronic and hydrophobicity parameters on psychotomimetic phenylalkylamines. Theochem, 1996, 367(1), 139-149. (Pubitemid 126387615)
72. Lobos, M.; Borges, Y.; Gonzalez, E.; Cassels, B.K. The action of the psychoactive drug 2C-B on isolated rat thoracic aorta. Gen. Pharmacol., 1992, 23(6), 1139-1142.
73. Saez, P.; Borges, Y.; Gonzalez, E.; Cassels, B.K. Alpha-adrenergic and 5-HT2-serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta. Gen. Pharmacol., 1994, 25(1), 211-216. (Pubitemid 2032368)
74. Cole, M.D.; Lea, C.; Oxley, N. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. Sci. Justice, 2002, 42(4), 223-224. (Pubitemid 36232206)
75. Drug Enforcement Administration - Office of Forensic Sciences BZP and Nexus tablets. Microgram, 2001, 34(1), 3.
76. Drug Enforcement Administration - Office of Forensic Sciences 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7). Microgram, 2001, 34(8), 193.
77. Drug Enforcement Administration - Office of Forensic Sciences Dipropyltryptamine and 2C-I in Portland, Oregon. Microgram, 2004, 37(6), 113-114.
78. Drug Enforcement Administration - Office of Forensic Sciences 2C-I tablets in the balearic islands (spain). Microgram, 2004, 37(3), 48-49.
79. Drug Enforcement Administration - Office of Forensic Sciences 2,5-Dimethoxy-4-Ethylphenethylamine (2C-E) Encountered In FT. Pierce, Florida and Royal Oak, Michigan. Microgram, 2004, 37(11), 193-194.
80. Drug Enforcement Administration - Office of Forensic Sciences 2,5-Dimethoxy-4-Ethylphenethylamine (2C-E) Capsules In Bettendorf, Iowa. Microgram, 2005, 38(4), 59.
81. Kanamori, T.; Inoue, H.; Iwata, Y.; Ohmae, Y.; Kishi, T. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J. Anal. Toxicol., 2002, 26(2), 61-66. (Pubitemid 34201780)
82. Kanamori, T.; Tsujikawa, K.; Ohmae, Y.; Iwata, Y.; Inoue, H.; Inouye, Y.; Kishi, T. Excretory profile of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rat. J. Health Sci., 2003, 49(2), 166-169. (Pubitemid 41301485)
83. Kanamori, T.; Tsujikawa, K.; Ohmae, Y.; Iwata, Y.T.; Inoue, H.; Kishi, T.; Nakahama, T.; Inouye, Y. A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forensic Sci. Int., 2005, 148(2-3), 131-137. (Pubitemid 40082402)
84. Maurer, H.H.; Pfleger, K.; Weber, A.A. Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites, 3rd ed.; Wiley-VCH: Weinheim, 2007.
85. de Boer, D.; dos Reys, L.A.; Pylon, N.; Gijzels, M.; Bosman, I.J.; Maes, R.A.A. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5- dimethoxyphenethylamine) and its metabolites In humans. Br. J. Pharmacol., 1999, 127(Proceedings Supplement), 41P.
86. Carmo, H.; Boer, D.; Remiao, F.; Carvalho, F.; Reys, L.A.; Bastos, M.L. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 811(2), 143-152.
87. Carmo, H.; Hengstler, J.G.; de Boer, D.; Ringel, M.; Remiao, F.; Carvalho, F.; Fernandes, E.; dos Reys, L.A.; Oesch, F.; De Lourdes, B.M. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology, 2005, 206(1), 75-89.
88. Braun, U.; Shulgin, A.T.; Braun, G.; Sargent, T. III Synthesis and body distribution of several iodine-131 labeled centrally acting drugs. J. Med. Chem., 1977, 20(12), 1543-1546.
89. Drees, J.C.; Stone, J.A.; Wu, A.H. Morbidity involving the hallucinogenic designer amines MDA and 2C-I. J. Forensic Sci, 2009, 54(6), 1485-1487.
90. Allred, R.A. Spectral characterization of 2,4-dimethoxy-3- methylphenethylamine, and comparison to 2,5-dimethoxy-4-methylphenetylamine (2C-D). Microgram. J., 2005, 3(1-2), 16-26.
91. Lood, Y.; Eklund, A. In Abstract book of the 43rd International SOFT/TIAFT Meeting in Washington; LeBeau, M., Ed.; TIAFT2004: Washington (DC), 2004; pp. 115.
92. Drug Enforcement Administration - Office of Forensic Sciences Unusual polydrug seizure in Ellsworth, Kansas. Microgram, 2004, 37(1), 8.
93. Lin, L.C.; Liu, J.T.; Chou, S.H.; Lin, C.H. Identification of 2,5-dimethoxy-4-ethylthiophenethylamine and its metabolites in the urine of rats by gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 798(2), 241-247. (Pubitemid 37487723)
94. Curtis, B.; Kemp, P.; Harty, L.; Choi, C.; Christensen, D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J. Anal. Toxicol., 2003, 27(7), 493-498. (Pubitemid 37185861)
95. Kanamori, T.; Kuwayama, K.; Tsujikawa, K.; Miyaguchi, H.; Iwata, Y.T.; Inoue, H.; Kishi, T. In vivo metabolism of 2,5-dimethoxy-4- propylthiophenethylamine in rat. Xenobiotica, 2007, 37(6), 679-692.
96. Carmo, H.; Hengstler, J.G.; de Boer, D.; Ringel, M.; Carvalho, F.; Fernandes, E.; Remiao, F.; dos Reys, L.A.; Oesch, F.; De Lourdes, B.M. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 369(2), 198-205.
97. Theobald, D.S.; Maurer, H.H. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem. Pharmacol., 2007, 73(2), 287-297.
98. Nandigama, R.K.; Edmondson, D.E. Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry, 2000, 39(49), 15258-15265.
99. Bossong, M.G.; Van Dijk, J.P.; Niesink, R.J. Methylone and mCPP, two new drugs of abuse? Addict. Biol, 2005, 10(4), 321-323.
100. Shimizu, E.; Watanabe, H.; Kojima, T.; Hagiwara, H.; Fujisaki, M.; Miyatake, R.; Hashimoto, K.; Iyo, M. Combined intoxication with methylone and 5-MeO-MIPT. Prog. Neuropsychopharmacol. Biol Psychiatry, 2007, 31(1), 288-291.
101. Nagai, F.; Nonaka, R.; Satoh Hisashi, K.K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol., 2007, 559(2-3), 132-137. (Pubitemid 46295399)
102. Shimizu, E.; Watanabe, H.; Kojima, T.; Hagiwara, H.; Fujisaki, M.; Miyatake, R.; Hashimoto, K.; Iyo, M. Combined intoxication with methylone and 5-MeO-MIPT. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(1), 288-291.
103. Peters, F.T.; Meyer, M.R.; Fritschi, G.; Maurer, H.H. In Proceedings of the XIVth GTFCh Symposium in Mosbach 2005; Pragst, F.; Aderjan, R., Eds.; Helm-Verlag: Heppenheim (Germany), 2006; pp. 184-191.
104. Springer, D.; Peters, F.T.; Fritschi, G.; Maurer, H.H. GC-MS studies on the metabolism and toxicological analysis of the new pyrrolidino-hexanophenone designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP). Ann. Toxicol. Anal., 2002, 14(3), 212.
105. Meyer, M.R.; Wilhelm, J.; Peters, F.T.; Maurer, H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem., 2010, 397(3), 1225-1233.
106. Roesner, P.; Junge, T.; Fritschi, G.; Klein, B.; Thielert, K.; Kozlowski, M. Neue synthetische Drogen: Piperazin-, Procyclidinund alpha- Aminopropiophenonderivate. Toxichem. Krimtech., 1999, 66(2), 81-90.
107. Fauquet, J.P.; Morel, E.; Demarty, C.; Rapin, J.R. [Role of central catecholamines in the psychostimulant activity of pyrovalerone]. Arch. Int. Pharmacodyn. Ther., 1976, 224(2), 325-337.
108. Servin, A.; Fauquet, J.P.; Jacquot, C.; Rapin, J.R. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem. Pharmacol., 1978, 27(12), 1693-1694. (Pubitemid 9010296)
109. Goldberg, J.; Gardos, G.; Cole, J.O. A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int. Pharmacopsychiatry, 1973, 8(1), 60-69.
110. Meltzer, P.C.; Butler, D.; Deschamps, J.R.; Madras, B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J. Med. Chem., 2006, 49(4), 1420-1432.
111. Stille, G.; Ackermann, H.; Eichenberger, E.; Lauener, H. [Comparative pharmacological study of a new central stimulant, 1-p-tolyl-1-oxo-2-pyrrolidino- n-pentane HCl]. Arzneim. -Forsch., 1963, 13, 871-877.
112. Deniker, P.; Loo, H.; Cuche, H.; Roux, J.M. [Abuse of pyrovalerone by drug addicts]. Ann. Med. Psychol. (Paris), 1975, 2(4), 745-748.
113. Vickers, S.; Polsky, S.L. The biotransformation of nitrogen containing xenobiotics to lactams. Curr. Drug Metab., 2000, 1(4), 357-389.
114. Peters, F.T.; Meyer, M.R.; Theobald, D.S.; Maurer, H.H. Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methyl- pyrrolidino-butyrophenone (MPBP), a new designer drug, in human liver microsomes. Drug Metab. Dispos., 2008, 36(1), 163-168.
115. Maddox, V.H.; Godefroi, E.F.; Parcell, R.F. Synthesis of Phencyclidine and Other 1-Arylcyclohexylamines. J. Med. Chem., 1965, 8(2), 230-235.
116. Rang, H.P.; Dale, M.M.; Ritter, J.M. Pharmacology, 4th ed.; Churchill Livingston: London, 1999.
117. Takeda, H.; Gazzara, R.A.; Howard, S.G. Phenylcyclohexylamine: effect of a metabolite of phencyclidine on the efflux of dopamine in the rat. Neuropharmacology, 1986, 25(12), 1341-1345.
118. Sauer, C.; Peters, F.T.; Staack, R.F.; Fritschi, G.; Maurer, H.H. In Proceedings of the XIVth GTFCh Symposium in Mosbach 2005; Pragst, F.; Aderjan, R. Eds.; Helm-Verlag: Heppenheim (Germany), 2006; pp. 192-197.
119. Sauer, C.; Peters, F.T.; Schwaninger, A.E.; Meyer, M.R.; Maurer, H.H. Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the Designer Drugs N-(1-Phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) and N-(1-Phenylcyclohexyl)-3-methoxypropanamine (PCMPA). Chem. Res. Toxicol., 2008, 21(10), 1949-1955.
120. Sauer, C.; Peters, F.T.; Schwaninger, A.E.; Meyer, M.R.; Maurer, H.H. Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochem. Pharmacol., 2009, 77(3), 444-450.
121. Crespi, C.L. In: Advances in Drug Research, 26th ed.; Testa, B.; Meyer, U.A., Eds.; Academic Press: London, 1995; pp. 179-235.
122. Crespi, C.L.; Penman, B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv. Pharmacol., 1997, 43 171-188.
123. Venkatakrishnan, K.; von Moltke, L.L.; Court M.H.; Harmatz, J.S.; Crespi, C.L.; Greenblatt, D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos., 2000, 28(12), 1493-1504.
124. Sauer, C.; Peters, F.T.; Staack, R.F.; Fritschi, G.; Maurer, H.H. In: Current Contributions to Forensic and Clinical Toxicology; Pragst, F.; Aderjan, R., Eds.; GTFCh: Bad Vilbel (Germany), 2008; pp. 204-210.
125. Turpeinen, M.; Raunio, H.; Pelkonen, O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab., 2006, 7(7), 705-714. (Pubitemid 44509677)
126. Rae, J.M.; Soukhova, N.V.; Flockhart, D.A.; Desta, Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab. Dispos., 2002, 30(5), 525-530. (Pubitemid 34456973)
127. Hesse, L.M.; Venkatakrishnan, K.; Court MH; von Moltke, L.L.; Duan, S.X.; Shader, R.I.; Greenblatt, D.J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos., 2000, 28(10), 1176-1183.
128. Chambers, J.J.; Kurrasch-Orbaugh, D.M.; Parker, M.A.; Nichols, D.E. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J. Med. Chem., 2001, 44(6), 1003-1010.
129. O'Brien, C.P. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J.G.; Limbird, L.E.; Molinoff, P.M.; Ruddon, R.W.; Gilman, A., Eds.; McGraw-Hill: New York, 1996; pp. 573.
130. Narimatsu, S.; Yonemoto, R.; Saito, K.; Takaya, K.; Kumamoto, T.; Ishikawa, T.; Asanuma, M.; Funada, M.; Kiryu, K.; Naito, S.; Yoshida, Y.; Yamamoto, S.; Hanioka, N. Oxidative metabolism of 5-methoxy-N,N- diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem. Pharmacol., 2006, 71(9), 1377-1385.
131. Narimatsu, S.; Yonemoto, R.; Masuda, K.; Katsu, T.; Asanuma, M.; Kamata, T.; Katagi, M.; Tsuchihashi, H.; Kumamoto, T.; Ishikawa, T.; Naito, S.; Yamano, S.; Hanioka, N. Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem. Pharmacol., 2008, 75(3), 752-760.
132. Fantegrossi, W.E.; Harrington, A.W.; Kiessel, C.L.; Eckler, J.R.; Rabin, R.A.; Winter, J.C.; Coop, A.; Rice, K.C.; Woods, J.H. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol. Biochem. Behav., 2006, 83(1), 122-129.
133. Kamata, T.; Katagi, M.; Kamata, H.T.; Miki, A.; Shima, N.; Zaitsu, K.; Nishikawa, M.; Tanaka, E.; Honda, K.; Tsuchihashi, H. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. Drug Metab. Dispos., 2006, 34(2), 281-287. (Pubitemid 43145029)
134. Kanamori, T.; Kuwayama, K.; Tsujikawa, K.; Miyaguchi, H.; Iwata, Y.; Inoue, H.; Kishi, T. In vivo metabolism of 5-methoxy-N,N-diisopropyltryptamine in rat. J. Health Sci., 2006, 52(4), 425-430.
135. Henderson, G.L. Designer drugs: past history and future prospects. J. Forensic Sci., 1988, 33(2), 569-575. (Pubitemid 18087762)
136. Van Bever, W.F.; Niemegeers, C.J.; Janssen, P.A. Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-
137. Sato, S.; Suzuki, S.; Lee, X.P.; Sato, K. Studies on 1-(2-phenethyl)-4- (N-propionylanilino)piperidine (fentanyl) and related compounds VII. Quantification of alpha-methylfentanyl metabolites excreted in rat urine. Forensic Sci. Int., 2010, 195(1-3), 68-72.
138. Hammargren, W.R.; Henderson, G.L. Analyzing normetabolites of the fentanyls by gas chromatography/electron capture detection. J. Anal. Toxicol., 1988, 12(4), 183-191.